Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. Issue 10 (October 2018)

• Record Type: Journal Article
• Authors: Obad, Nina; Espedal, Heidi; Jirik, Radovan; Sakariassen, Per Oystein; Brekke Rygh, Cecilie; Lund-Johansen, Morten; Taxt, Torfinn; Niclou, Simone P; Bjerkvig, Rolf; Keunen, Olivier
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 38:Issue 10(2018)
• Page Start: 1741
• Page End: 1753
• Publication Date: 2018-10
• Subjects: Angiogenesis -- bevacizumab -- glioblastoma -- hypoxia -- perfusion -- VEGF; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X17714656
• Languages: English
• ISSNs: 0271-678X

Abstract

Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known. The presented study aimed at determining the early physiologic changes following bevacizumab treatment. A time series of perfusion MRI and hypoxia positron emission tomography (PET) scans were acquired during the first week of treatment, in two human GBM xenograft models treated with either high or low doses of bevacizumab. We show that vascular morphology was normalised over the time period investigated, but vascular function was not improved, resulting in poor tumoural blood flow and increased hypoxia.